UY33628A - Nuevo monohidrato de derivados de aza-adamantano - Google Patents
Nuevo monohidrato de derivados de aza-adamantanoInfo
- Publication number
- UY33628A UY33628A UY0001033628A UY33628A UY33628A UY 33628 A UY33628 A UY 33628A UY 0001033628 A UY0001033628 A UY 0001033628A UY 33628 A UY33628 A UY 33628A UY 33628 A UY33628 A UY 33628A
- Authority
- UY
- Uruguay
- Prior art keywords
- monohidrate
- new aza
- adamantan
- derivatives
- adamantan derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Communicable Diseases (AREA)
Abstract
Forma cristalina monohidrato del citrato diácido de (4s)-4-(5-fenil-1,3,4-tiadiazol-2-iloxi)-1-azatriciclo[3.3.1.13,7]decano, composiciones que comprenden dicho compuesto y un proceso para preparar el compuesto.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38567410P | 2010-09-23 | 2010-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33628A true UY33628A (es) | 2012-03-30 |
Family
ID=44736085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033628A UY33628A (es) | 2010-09-23 | 2011-09-23 | Nuevo monohidrato de derivados de aza-adamantano |
Country Status (24)
Country | Link |
---|---|
US (2) | US9464078B2 (es) |
EP (1) | EP2619205B1 (es) |
JP (2) | JP2013537912A (es) |
KR (1) | KR20130108586A (es) |
CN (2) | CN106074548A (es) |
AR (1) | AR083100A1 (es) |
AU (1) | AU2011305462B2 (es) |
BR (2) | BR112013005434A2 (es) |
CA (1) | CA2809675A1 (es) |
CL (2) | CL2013000756A1 (es) |
CO (1) | CO6720965A2 (es) |
CR (2) | CR20130169A (es) |
DO (2) | DOP2013000064A (es) |
EC (1) | ECSP13012575A (es) |
GT (1) | GT201300064A (es) |
MX (1) | MX2013003344A (es) |
NZ (2) | NZ707955A (es) |
PE (1) | PE20131394A1 (es) |
RU (2) | RU2579121C2 (es) |
SG (2) | SG2014013460A (es) |
TW (2) | TW201626996A (es) |
UA (1) | UA110802C2 (es) |
UY (1) | UY33628A (es) |
WO (1) | WO2012040404A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
US9464078B2 (en) | 2010-09-23 | 2016-10-11 | Abbvie Inc. | Monohydrate of azaadamantane derivatives |
US8802693B1 (en) | 2011-03-09 | 2014-08-12 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
US20130317055A1 (en) * | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Neuronal nicotinic agonist and methods of use |
US8969562B2 (en) | 2013-03-12 | 2015-03-03 | Abbvie, Inc. | Azaadamantane formate ester and process for preparing azaadamantane derivatives |
AU2014361790B2 (en) * | 2013-12-13 | 2019-05-23 | Allergan, Inc. | Polymorphic and amorphous forms of cortisol 17-alpha-benzoate and methods for the preparation and use thereof |
AU2015362790A1 (en) | 2014-12-16 | 2017-07-20 | Axovant Sciences Gmbh | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
CA2988968A1 (en) | 2015-06-10 | 2016-12-15 | Forum Pharmaceuticals, Inc. | Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors |
WO2017027600A1 (en) | 2015-08-12 | 2017-02-16 | Forum Pharmaceuticals, Inc. | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2514006A1 (fr) | 1981-10-05 | 1983-04-08 | Nativelle Sa Ets | Acylamino-4 aza-1 adamantanes, procede pour leur preparation, et application en therapeutique |
EP0088484A1 (en) | 1982-02-04 | 1983-09-14 | Fbc Limited | Herbicidal thiadiazolyl N-aminoureas |
GB8523211D0 (en) | 1985-09-19 | 1985-10-23 | Beecham Group Plc | Compounds |
US4950759A (en) | 1988-07-07 | 1990-08-21 | Duphar International Research B.V. | Substituted 1,7-annelated 1H-indazoles |
US5260303A (en) | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
AU1752792A (en) | 1991-03-08 | 1992-10-06 | Rhone-Poulenc Rorer International (Holdings) Inc. | Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors |
US5385912A (en) | 1991-03-08 | 1995-01-31 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Multicyclic tertiary amine polyaromatic squalene synthase inhibitors |
US5280028A (en) | 1992-06-24 | 1994-01-18 | G. D. Searle & Co. | Benzimidazole compounds |
US5434151A (en) | 1992-08-24 | 1995-07-18 | Cytomed, Inc. | Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase |
US5840903A (en) | 1992-07-27 | 1998-11-24 | G. D. Searle & Co. | 4-aminomethyl-1-azaadamantane derived benzamides |
JP3235913B2 (ja) | 1993-07-30 | 2001-12-04 | エーザイ株式会社 | アミノ安息香酸誘導体 |
US5399562A (en) | 1994-02-04 | 1995-03-21 | G. D. Searle & Co. | Indolones useful as serotonergic agents |
US5821370A (en) | 1994-10-24 | 1998-10-13 | Eli Lilly And Company | Heterocyclic compounds and their preparation and use |
US5852037A (en) | 1995-11-13 | 1998-12-22 | Eli Lilly And Company | Method for treating anxiety |
US5998434A (en) | 1995-12-06 | 1999-12-07 | Eli Lilly And Company | Composition for treating pain |
AU7871498A (en) | 1996-12-20 | 1998-07-17 | Novo Nordisk A/S | A method of treating hypercholesterolemia and related disorders |
US7732163B2 (en) | 1997-08-21 | 2010-06-08 | Board Of Trustees Of The University Of Arkansas | Extracellular serine protease |
US6875606B1 (en) | 1997-10-23 | 2005-04-05 | The United States Of America As Represented By The Department Of Veterans Affairs | Human α-7 nicotinic receptor promoter |
US8236500B2 (en) | 1997-10-23 | 2012-08-07 | The United States Of America, As Represented By The Department Of Veterans Affairs | Promoter variants of the alpha-7 nicotinic acetylcholine receptor |
EP2295436A1 (de) | 1997-11-12 | 2011-03-16 | Bayer Schering Pharma AG | 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren |
US6057446A (en) | 1998-04-02 | 2000-05-02 | Crooks; Peter Anthony | Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds |
AU2892999A (en) | 1998-04-02 | 1999-10-25 | R.J. Reynolds Tobacco Company | Azatricyclo(3.3.1.1) decane derivatives and pharmaceutical compositions containing them |
US5986100A (en) | 1998-04-02 | 1999-11-16 | Crooks; Peter Anthony | Pharmaceutical compositions and methods for use |
US5952339A (en) | 1998-04-02 | 1999-09-14 | Bencherif; Merouane | Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release |
US6277870B1 (en) | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
EP1083889B1 (en) | 1998-06-01 | 2003-12-10 | Ortho-McNeil Pharmaceutical, Inc. | Tetrahydronaphtalene compounds and their use for the treatment of neurodegenerative diseases |
ATE227724T1 (de) | 1998-08-18 | 2002-11-15 | Ucb Sa | Muscarinagonisten und antagonisten |
NZ513575A (en) | 1999-05-04 | 2003-07-25 | Neurosearch As | Heteroaryl diazabicycloalkanes useful for treating or preventing a disease or a disorder responsive to the activity of nAChR modulators |
US20010031771A1 (en) | 1999-05-24 | 2001-10-18 | Gary Maurice Dull | Pharmaceutical compositions and methods for use |
AU4667800A (en) | 1999-05-24 | 2000-12-12 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
WO2001040261A1 (en) | 1999-12-01 | 2001-06-07 | Ortho-Mcneil Pharmaceutical, Inc. | Method of diagnosing neurodegenerative disease |
AU2001257449A1 (en) | 2000-05-01 | 2001-11-12 | Targacept, Inc. | Imaging of nicotinic acetylcholine receptor subtypes |
DE60108639T2 (de) | 2000-07-04 | 2005-07-07 | Neurosearch A/S | Aryl- und heteroaryldiazabicycloalkane, deren zubereitung und verwendung |
AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
JP4225787B2 (ja) | 2001-03-27 | 2009-02-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | N−アリール環状アミン誘導体およびそれを有効成分として含有する医薬 |
US6939515B2 (en) * | 2001-08-10 | 2005-09-06 | Symyx Technologies, Inc. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
FR2832713B1 (fr) | 2001-11-23 | 2004-02-13 | Sanofi Synthelabo | Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique |
CN100371714C (zh) | 2001-12-14 | 2008-02-27 | 塔加西普特公司 | 治疗中枢神经系统病症的方法和组合物 |
DE60310548T2 (de) | 2002-05-07 | 2007-05-10 | Neurosearch A/S | Diazabicyclische biarylderivate |
US7049374B2 (en) | 2002-07-18 | 2006-05-23 | Chevron U.S.A. Inc. | Heterodiamondoids |
WO2004016608A1 (en) | 2002-08-14 | 2004-02-26 | Neurosearch A/S | Novel quinuclidine derivatives and their use |
US7030112B2 (en) | 2003-03-25 | 2006-04-18 | Bristol-Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
US7135454B2 (en) | 2003-04-16 | 2006-11-14 | Applied Research Systems Ars Holding N.V. | Use of SLURP-1 compositions for treating schizophrenia |
US7202363B2 (en) | 2003-07-24 | 2007-04-10 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
AU2004268621C1 (en) | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
US7399765B2 (en) | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
TWI331154B (en) | 2003-11-12 | 2010-10-01 | Solvay Pharm Gmbh | Novel 17-hydroxysteroid dehydrogenase type i inhibitors |
WO2006065233A1 (en) | 2004-12-10 | 2006-06-22 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
JP2005232071A (ja) | 2004-02-19 | 2005-09-02 | Kanto Chem Co Inc | ピラゾール誘導体 |
MXPA06012595A (es) | 2004-04-29 | 2007-05-09 | Abbott Lab | Analogos de amino-tetrazoles y metodos de uso. |
MY148480A (en) | 2004-05-24 | 2013-04-30 | Amgen Inc | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
AR049401A1 (es) | 2004-06-18 | 2006-07-26 | Novartis Ag | Aza-biciclononanos |
FR2872165B1 (fr) | 2004-06-24 | 2006-09-22 | Sod Conseils Rech Applic | Nouveaux derives de pyrimido-benzimidazole |
GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
CN101087756B (zh) | 2004-07-23 | 2011-04-06 | 纽阿达有限责任公司 | 肽酶抑制剂 |
EP2208496A1 (en) | 2004-08-25 | 2010-07-21 | Essentialis, Inc. | Pharmaceutical formulations of potassium ATP channel openers and uses thereof |
CA2584836A1 (en) | 2004-10-15 | 2006-04-20 | Neurosearch A/S | Novel azabicyclic aryl derivatives and their medical use |
CA2584838A1 (en) | 2004-10-20 | 2006-05-04 | Neurosearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
EP1919497B1 (en) | 2005-07-22 | 2020-02-12 | The Board of Trustees of the Leland Stanford Junior University | Light-activated cation channel and uses thereof |
US20090093403A1 (en) | 2007-03-01 | 2009-04-09 | Feng Zhang | Systems, methods and compositions for optical stimulation of target cells |
US9274099B2 (en) | 2005-07-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Screening test drugs to identify their effects on cell membrane voltage-gated ion channel |
US7897766B2 (en) | 2005-09-23 | 2011-03-01 | Abbott Laboratories | Amino-aza-adamantane derivatives and methods of use |
US8173658B2 (en) | 2005-12-06 | 2012-05-08 | Neurosearch A/S | Diazabicycylic aryl derivatives and their medical use |
US20090291976A1 (en) | 2006-06-27 | 2009-11-26 | Peter Andrew Ferchmin | Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors |
FR2905009A1 (fr) | 2006-08-18 | 2008-02-22 | Servier Lab | Methode de criblage de composes aux proprietes anti-amyloide |
WO2008028903A2 (en) | 2006-09-04 | 2008-03-13 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
EP2420235A1 (en) | 2006-10-27 | 2012-02-22 | Medivation Neurology, Inc. | Methods and combination therapies for treating alzheimer's disease |
TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
CN101541792A (zh) * | 2006-11-06 | 2009-09-23 | 艾博特公司 | 氮杂金刚烷衍生物和应用方法 |
US8314119B2 (en) * | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
KR20090107567A (ko) | 2007-02-09 | 2009-10-13 | 아스텔라스세이야쿠 가부시키가이샤 | 아자 가교환 화합물 |
EP2126131A2 (en) | 2007-03-08 | 2009-12-02 | Genizon Biosciences, Inc. | Genemap of the human genes associated with schizophrenia |
WO2008118742A1 (en) | 2007-03-23 | 2008-10-02 | Abbott Laboratories | Azaadamantane ester and carbamate derivatives and methods of use thereof |
EP2322167A1 (en) | 2007-04-02 | 2011-05-18 | Parkinson's Institute | Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments |
WO2009017454A1 (en) | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
US8697722B2 (en) | 2007-11-02 | 2014-04-15 | Sri International | Nicotinic acetylcholine receptor modulators |
WO2009058120A1 (en) | 2007-11-02 | 2009-05-07 | Sri International | Nicotinic acetylcholine receptor modulators |
JP5436222B2 (ja) | 2007-11-20 | 2014-03-05 | 日産化学工業株式会社 | 2−アザアダマンタン類の製造方法 |
DE102007058504A1 (de) | 2007-12-05 | 2009-07-09 | Acino Ag | Transdermales therapeutisches System mit einem Gehalt an einem Modulator für nikotinische Acetylcholinrezeptoren (nAChR) |
MX2010008875A (es) | 2008-02-13 | 2010-08-31 | Targacept Inc | Agonistas nicotinicos alfa 7 y antipsicoticos. |
US20090239901A1 (en) | 2008-03-19 | 2009-09-24 | Merouane Bencherif | Method and compositions for treatment of cerebral malaria |
US20110098312A1 (en) | 2008-05-12 | 2011-04-28 | Targacept ,Inc | Methods for preventing the development of retinopathy by the oral administration of nnr ligands |
FR2931677B1 (fr) | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
EP2294082A4 (en) | 2008-06-13 | 2011-07-13 | Ct For Addiction And Mental Health | COMPOSITIONS AND METHOD FOR MODULATING THE NICOTIN / NMDA RECEPTOR FUNCTION |
WO2010030887A1 (en) | 2008-09-11 | 2010-03-18 | Catholic Healthcare West | Nicotinic attenuation of cns inflammation and autoimmunity |
EP2344636B1 (en) | 2008-10-09 | 2017-12-06 | Howard Hughes Medical Institute | Novel chimeric ligand-gated ion channels and methods of use thereof |
JP5657556B2 (ja) | 2008-11-11 | 2015-01-21 | ターガセプト,インコーポレイテッド | α7選択的リガンドを用いる治療 |
CA2750928A1 (en) | 2009-01-28 | 2010-08-05 | Catholic Healthcare West | Methods of diagnosing and treating neurodegenerative diseases |
MX2012001420A (es) | 2009-07-31 | 2012-03-26 | Biocryst Pharm Inc | Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus. |
AU2010284282A1 (en) | 2009-08-21 | 2012-04-12 | The Regents Of The University Of Colorado, A Body Corporate | Controlled-release formulations of anabaseine compounds and uses thereof |
WO2011044537A2 (en) | 2009-10-09 | 2011-04-14 | Afraxis, Inc. | Methods for treating alzheimer's disease |
WO2011058582A1 (en) | 2009-11-16 | 2011-05-19 | Orchid Research Laboratories Ltd. | Histone deacetylase inhibitors for the treatment of fungal infections |
US9464078B2 (en) | 2010-09-23 | 2016-10-11 | Abbvie Inc. | Monohydrate of azaadamantane derivatives |
EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
WO2012059932A1 (en) | 2010-11-01 | 2012-05-10 | Aurigene Discovery Technologies Limited | 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors |
-
2011
- 2011-09-21 US US13/238,239 patent/US9464078B2/en not_active Expired - Fee Related
- 2011-09-21 RU RU2013118560/04A patent/RU2579121C2/ru not_active IP Right Cessation
- 2011-09-21 SG SG2014013460A patent/SG2014013460A/en unknown
- 2011-09-21 EP EP11764428.6A patent/EP2619205B1/en active Active
- 2011-09-21 PE PE2013000540A patent/PE20131394A1/es not_active Application Discontinuation
- 2011-09-21 RU RU2016105706A patent/RU2016105706A/ru not_active Application Discontinuation
- 2011-09-21 JP JP2013530292A patent/JP2013537912A/ja active Pending
- 2011-09-21 BR BR112013005434A patent/BR112013005434A2/pt not_active IP Right Cessation
- 2011-09-21 BR BR122014023207-1A patent/BR122014023207A2/pt not_active IP Right Cessation
- 2011-09-21 MX MX2013003344A patent/MX2013003344A/es unknown
- 2011-09-21 NZ NZ707955A patent/NZ707955A/en not_active IP Right Cessation
- 2011-09-21 AU AU2011305462A patent/AU2011305462B2/en not_active Ceased
- 2011-09-21 CN CN201610412845.0A patent/CN106074548A/zh active Pending
- 2011-09-21 UA UAA201305205A patent/UA110802C2/uk unknown
- 2011-09-21 NZ NZ609761A patent/NZ609761A/en not_active IP Right Cessation
- 2011-09-21 KR KR1020137010192A patent/KR20130108586A/ko not_active Application Discontinuation
- 2011-09-21 CA CA2809675A patent/CA2809675A1/en not_active Abandoned
- 2011-09-21 WO PCT/US2011/052668 patent/WO2012040404A1/en active Application Filing
- 2011-09-21 CN CN2011800458669A patent/CN103180321A/zh active Pending
- 2011-09-21 SG SG2013014329A patent/SG188307A1/en unknown
- 2011-09-23 UY UY0001033628A patent/UY33628A/es unknown
- 2011-09-23 TW TW105100070A patent/TW201626996A/zh unknown
- 2011-09-23 TW TW100134437A patent/TW201212914A/zh unknown
- 2011-09-23 AR ARP110103496A patent/AR083100A1/es unknown
-
2013
- 2013-03-12 GT GT201300064A patent/GT201300064A/es unknown
- 2013-03-20 CL CL2013000756A patent/CL2013000756A1/es unknown
- 2013-03-22 DO DO2013000064A patent/DOP2013000064A/es unknown
- 2013-04-15 CR CR20130169A patent/CR20130169A/es unknown
- 2013-04-17 CO CO13098843A patent/CO6720965A2/es not_active Application Discontinuation
- 2013-04-23 EC ECSP13012575 patent/ECSP13012575A/es unknown
- 2013-07-17 DO DO2013000249A patent/DOP2013000249A/es unknown
- 2013-11-14 CR CR20130594A patent/CR20130594A/es unknown
-
2014
- 2014-03-18 CL CL2014000651A patent/CL2014000651A1/es unknown
-
2015
- 2015-05-08 US US14/707,681 patent/US20150239882A1/en not_active Abandoned
-
2016
- 2016-10-21 JP JP2016206552A patent/JP2017039764A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY33628A (es) | Nuevo monohidrato de derivados de aza-adamantano | |
PH12016501375A1 (en) | Pyridin-2-amides useful as cb2 agonists | |
MX2010012298A (es) | Activadores de glucocinasa. | |
MY150542A (en) | Cmet inhibitors | |
PA8827101A1 (es) | Derivados de indazoles sustituidos con fenilo o piridinilo | |
CR20120277A (es) | Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa | |
MY170878A (en) | [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 | |
MY186599A (en) | Substituted pyridopyrazines as novel syk inhibitors | |
CR20140546A (es) | Forma cristalina a de 1,5-dimetil-6-tioxo-3- (2,2,7-trifluoro- 3-oxo-4- (prop-2-inil)-3,4-dihidro -2h-benzo [b] [1,4] oxazin-6-il)-1,3,5- triazinan-2,4-diona | |
CL2012003491A1 (es) | Compuesto derivado de dihidropirrol sustituidos; proceso para preparar dichos derivados en forma estereoselectiva. | |
CL2013001221A1 (es) | Compuesto clorhidrato de (4a-r, 9a-s)-1-(1h-benzoimidazol-5-carbonil-2,3,4,4a,9,9a-hexahidro-1 h-inden[2,1-b] piridin-6-carbonitrilo y sus formas cristalinas i y ii, inhibidores de hsd 1; composicion farmaceutica; metodo para producir la forma cristalina i del compuesto; metodo para producir la forma cristalina ii del compuesto. | |
EA201101116A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
IN2014DN10669A (es) | ||
GB201107985D0 (en) | Process | |
CL2011003123A1 (es) | Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras. | |
MX342960B (es) | Derivados de cromeno. | |
MX2015016766A (es) | Nuevos derivados de tetrazolona. | |
CO7200259A2 (es) | Nuevos derivados de piridina | |
ECSP11011150A (es) | Derivados de arilciclopropilacetamida útiles como activadores de glucoquinasa | |
CL2012000350A1 (es) | Combinacion farmaceutica que comprende un compuesto derivado de bifenilamida y un agente inhibidor de bcr-abl seleccionado de nilotinib; composicion farmaceutica; y uso de la combinacion para el tratamiento de leucemia positiva a bcr-abl. | |
EA201400882A1 (ru) | Способ стереоселективного синтеза 9-гидрокси-5-оксо-1,4-диазаспиро[5.5]ундеканов, содержащих защитные группы в 1,4-положениях | |
SA114350383B1 (ar) | عملية لتخليق مركبات 7، 8 - داي ميثوكسي - 1 ،3- داي هيدرو -h2 -3- بنزازيبين -2- أون، وتطبيقها في تخليق إيفابرادين | |
PA8786501A1 (es) | Proceso para preparar carboxaldehido oxazina biciclico e inhibidores de beta lactamasa | |
TN2011000020A1 (en) | cMET INHIBITORS |